Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 11—November 2023
Dispatch

Racial and Socioeconomic Equity of Tecovirimat Treatment during the 2022 Mpox Emergency, New York, New York, USA

Maura K. Lash1Comments to Author , Ned H. Latham1, Pui Ying Chan, Mary M.K. Foote, Elizabeth A. Garcia, Matthew F. Silverstein, Marcia Wong, Mark Alexander, Karen A. Alroy, Lovedeep Bajaj, Kuan Chen, James Steele Howard, Lucretia E. Jones, Ellen H. Lee, Julian L. Watkins, and Tristan D. McPherson
Author affiliations: New York City Department of Health and Mental Hygiene, Queens, New York, USA (M.K. Lash, N.H. Latham, P.Y. Chan, M.M.K. Foote, E.A. Garcia, M.F. Silverstein, M. Wong, M. Alexander, K.A. Alroy, L. Bajaj, K. Chen, J.S. Howard, L.E. Jones, E.H. Lee, J.L. Watkins, T.D. McPherson); Columbia University, New York, New York, USA (N.H. Latham)

Main Article

Table

Characteristics of persons with mpox according to treatment status in study of racial and socioeconomic equity of tecovirimat treatment during 2022 mpox emergency, New York City, New York, USA, May 19, 2022–October 29, 2022*

Characteristics Overall Tecovirimat treatment No treatment p value
Total no. persons
3,740 (100)
1,213 (32.4)
2,527 (67.6)
NA
Median age (IQR)
35 (12)
36 (11)
35 (12)
ND
Mean age (SD)
37 (9.4)
37 (9)
36 (9.5)
0.004
Age groups, y <0.001
0–24 255 (6.8) 55 (4.5) 200 (7.9)
25–34 1,527 (40.8) 471 (38.8) 1,056 (41.8)
35–44 1,265 (33.8) 449 (37.0) 816 (32.3)
45–54 507 (13.6) 177 (14.6) 330 (13.1)
55–64 166 (4.4) 55 (4.5) 111 (4.4)
>65
20 (0.5)
6 (0.5)
14 (0.6)

Gender† 0.01
Men 3,516 (94.2) 1,133 (93.5) 2,383 (94.6)
Nonbinary/gender queer 52 (1.4) 22 (1.8) 30 (1.2)
Transgender men or women 70 (1.9) 33 (2.7) 37 (1.5)
Women 93 (2.5) 24 (2.0) 69 (2.7)
Unknown
9
1
8

Sexual orientation <0.001
LGBQ+ 2,409 (64.4) 857 (70.7) 1,552 (61.4)
Straight 296 (7.9) 61 (5.0) 235 (9.3)
Unknown‡
1,035 (27.7)
295 (24.3)
740 (29.3)

Race/ethnicity§ <0.001
Asian/Pacific Islander/other 196 (5.2) 59 (4.9) 137 (5.4)
Black/African American 1,017 (27.2) 318 (26.2) 699 (27.7)
Hispanic/Latino 1,294 (34.6) 400 (33.0) 894 (35.4)
White 847 (22.7) 329 (27.1) 518 (20.5)
Unknown‡
386 (10.3)
107 (8.8)
279 (11.0)

Borough of residence <0.001
Bronx 729 (19.5) 259 (21.4) 470 (18.6)
Brooklyn 888 (23.7) 299 (24.6) 589 (23.3)
Manhattan 1,480 (39.5) 504 (41.5) 976 (38.7)
Queens 596 (15.9) 139 (11.5) 457 (18.1)
Staten Island 45 (1.2) 12 (1.0) 33 (1.3)
Unknown
2
0
2

Neighborhood poverty level¶ 0.53
Low 579 (15.5) 177 (14.6) 402 (16.0)
Medium 1588 (42.6) 508 (41.9) 1080 (42.9)
High 894 (24.0) 303 (25.0) 591 (23.5)
Very High 668 (17.9) 223 (18.4) 445 (17.7)
Unknown# 11 2 9

*Values are no. (%) except as indicated. IQR, interquartile range; LGBQ, lesbian, gay, bisexual, and queer; NA, not applicable; ND, not done. †Gender categories are provided as defined by the New York City Department of Health and Mental Hygiene. ‡Because of a substantial number of persons who had unknown sexual orientation or race/ethnicity, those persons were included as a separate category in the χ2 test. For other characteristics, people with unknown values were excluded from χ2 test. §All persons who identified as Hispanic or Latino (Hispanic), regardless of race, were classified as Hispanic; all other race/ethnicity categories were non-Hispanic. ¶Neighborhood poverty level was defined as the percentage of residents in a postal (ZIP) code tabulation area with household incomes of <100% of the federal poverty level according to the American Community Survey 2016–2020 (https://www.census.gov). Neighborhoods were categorized into 4 groups: low poverty, <10% of population; medium, 10%–19.9%; high, 20%–29.9%; and very high, >30%. #Unknown because of missing residential or invalid New York ZIP code.

Main Article

1These first authors contributed equally to this article.

Page created: September 26, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external